Jefferies Downgrades uniQure BV (QURE) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Futures ease as bond yields stay elevated amid Middle East tensions
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Asian shares slide on Fed rate cut rethink; China GDP in focus
- China Q1 GDP grows 5.3%, more than expected
- Oil slips as concern eases about Middle East supply risk
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress
November 22, 2016 7:06 AM EST~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its financial results for the third quarter ended September 30, 2016 and provided an update on corporate developments.
"With the completion of our company-wide strategic review, we have focused our pipeline, streamlined  operations... More
uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress
November 22, 2016 7:00 AM EST~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced its financial results for the third quarter ended September 30, 2016 and provided an update on corporate developments.
With the completion of our company-wide strategic review, we have focused our pipeline, streamlined... More
